- Home
- RRC vs CORT Comparison
RRC vs CORT Comparison
Compare RRC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RRC | CORT |
|---|---|---|
| Founded | 1976 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 7.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RRC | CORT |
|---|---|---|
| Price | $34.57 | $79.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 6 |
| Target Price | $41.94 | ★ $130.20 |
| AVG Volume (30 Days) | ★ 3.3M | 821.3K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 19.84 | N/A |
| EPS | ★ 2.38 | 0.87 |
| Revenue | ★ $2,891,506,000.00 | $741,172,000.00 |
| Revenue This Year | $28.16 | $23.79 |
| Revenue Next Year | $11.34 | $40.97 |
| P/E Ratio | ★ $14.50 | $92.87 |
| Revenue Growth | ★ 24.57 | 17.92 |
| 52 Week Low | $30.32 | $49.00 |
| 52 Week High | $43.50 | $117.33 |
Technical Indicators
Market Signals| Indicator | RRC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 49.32 |
| Support Level | $38.07 | $81.31 |
| Resistance Level | $40.88 | $89.00 |
| Average True Range (ATR) | 1.11 | 3.27 |
| MACD | -0.50 | 0.16 |
| Stochastic Oscillator | 9.32 | 29.77 |
Price Performance
Historical ComparisonAbout RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.